Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Subscribe To Our Newsletter & Stay Updated